Alliance C11001 Trial of Sorafenib with Chemotherapy for Older Adults with FLT3-ITD-Mutated AML


Alliance C11001 Trial of Sorafenib with Chemotherapy for Older Adults with FLT3-ITD-Mutated AML
Slides from a presentation at ASH 2015 and transcribed comments from a recent interview with Richard M Stone, MD (2/16/16)

Uy GL et al. Addition of sorafenib to chemotherapy improves the overall survival of older adults with FLT3-ITD mutated acute myeloid leukemia (AML) (Alliance C11001). Proc ASH 2015;Abstract 319.

Dr Stone is Director of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.